Status:
COMPLETED
Alvocade® (Bortezomib) Safety and Effectiveness Study
Lead Sponsor:
NanoAlvand
Conditions:
Multiple Myeloma, Refractory
Eligibility:
All Genders
Brief Summary
This study is a phase IV, post-marketing, observational, cohort study for safety and effectiveness evaluation of Alvocade® use in Iranian patients with multiple myeloma. No control groups were conside...
Detailed Description
This study is a phase IV, post-marketing, observational, cohort study for safety and effectiveness evaluation of Alvocade® use in Iranian patients with multiple myeloma. Data were gathered in two book...
Eligibility Criteria
Inclusion
- Patients with multiple myeloma were included in the study.
Exclusion
- There were no exclusion criteria for this study.
Key Trial Info
Start Date :
July 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2022
Estimated Enrollment :
57 Patients enrolled
Trial Details
Trial ID
NCT06012383
Start Date
July 1 2016
End Date
December 1 2022
Last Update
August 25 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.